Trial · NCT06736938
Balanced Analgosedation in Bronchoscopy: Propofol/Pethidine Versus Midazolam/Pethidine
NCT06736938, Phase 4, Not yet recruiting, Fondazione Andrea Cesalpino Arezzo ONLUS
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Balanced Analgosedation in Bronchoscopy: Propofol/Pethidine Versus Midazolam/Pethidine. Trials, record NCT06736938. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06736938
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Balanced Analgosedation in Bronchoscopy: Propofol/Pethidine Versus Midazolam/Pethidine
- NCT number
- NCT06736938
- Status
- Not yet recruiting
- Phases
- Phase 4
- Enrollment
- 530 participants, estimated
- Lead sponsor
- Fondazione Andrea Cesalpino Arezzo ONLUS
- Conditions
- Sedation During Bronchoscopy
- Interventions
- Propofol 1%, Midazolam, Pethidine
- First posted
- 2024-12-17
- Last updated
- 2024-12-17
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Desaturation Index | Trough study completion, an average of 2 years | The primary endpoint of this study is to evaluate and compare the desaturation index (SpO2 \< 90% for at least 30 seconds) between the two drug regimens. The analysis will be conducted both across all procedures and stratified by type (interventional vs simple); |
| Secondary | Blood Pressure | Trough study completion, an average of 2 years | This involves comparing the rates of peri- and post-procedural complications between the two treatment arms. * Hypotension defined by a systolic blood pressure \<90 mmHg or a diastolic blood pressure \<50 mmHg. * Hypotension requiring fluid therapy, vasoactive/inotropic therapy (yes or not). |
| Secondary | Heart Rate | Trough study completion, an average of 2 years | This involves comparing the rates of peri- and post-procedural complications between the two treatment arms. \- Bradycardia defined as a rate \<50 bpm requiring fluid therapy, vasoactive/inotropic therapy; |
| Secondary | Respiratory Effects | Trough study completion, an average of 2 years | This involves comparing the rates of peri- and post-procedural complications between the two treatment arms. \- Respiratory effects: bronchospasm or wheezing requiring systemic corticosteroids, aerosolized or systemic bronchodilator therapy (e.g., beta agonists, magnesium sulphate). |
| Secondary | Time in the recovery area | Trough study completion, an average of 2 years | Time spent in the recovery area (in minutes) |
| Secondary | A postanesthetic recovery score (Aldrete) | Trough study completion, an average of 2 years | Patient recovery assessed by Aldrete score. It evaluates a patient's recovery after anesthesia based on five criteria: activity, respiration, circulation, consciousness, and oxygen saturation. Each criterion is scored from 0 to 2, resulting in a total score ranging from 0 (minimum) to 10 (maximum). Investigators will consider patient recovery achieved with an Aldrete score ≥9. |
| Secondary | Rapid On Site Evaluation results | Trough study completion, an average of 2 years | i.e.: procedure with suitable sample (Yes or Not) |
| Secondary | Total desaturation time | Trough study completion, an average of 2 years | Total desaturation time is defined as the cumulative time a patient's oxygen saturation (SpO2) falls below a predefined threshold (SpO2\<90%) during the procedure. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers20
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06736938
GET https://conductscience.org/api/trials/v1/NCT06736938/registered